Literature DB >> 11773414

Oncoviral bovine leukemia virus G4 and human T-cell leukemia virus type 1 p13(II) accessory proteins interact with farnesyl pyrophosphate synthetase.

Laurent Lefèbvre1, Alain Vanderplasschen, Vincenzo Ciminale, Hubertine Heremans, Olivier Dangoisse, Jean-Claude Jauniaux, Jean-François Toussaint, Vlado Zelnik, Arsène Burny, Richard Kettmann, Luc Willems.   

Abstract

G4 and p13(II) are accessory proteins encoded by the X region of bovine leukemia virus and human T-cell leukemia virus type 1 (HTLV-1), respectively. Disruption of the G4 and p13(II) open reading frames interferes with viral spread in animal model systems, indicating that the corresponding proteins play a key role in viral replication. In addition, G4 is oncogenic in primary cell cultures and is absolutely required for efficient onset of leukemogenesis in sheep. To gain insight into the function of these proteins, we utilized the yeast two-hybrid system to identify protein partners of G4. Results revealed that G4 interacts with farnesyl pyrophosphate synthetase (FPPS), a protein involved in the mevalonate/squalene pathway and in synthesis of FPP, a substrate required for prenylation of Ras. The specificity of the interaction was verified by glutathione S-transferase (GST) pull-down assays and by coimmunoprecipitation experiments. Furthermore, confocal microscopy showed that the subcellular localization of G4 was profoundly affected by FPPS. The G4 protein itself was not prenylated, at least in rabbit reticulocyte lysate-based assays. The domain of G4 required for binding to FPPS was restricted to an amphipathic alpha-helix rich in arginine residues. Subtle mutation of this alpha-helix abrogated G4 oncogenic potential in vitro, providing a biological relevance for FPPS-G4 complex formation in cells. Finally, HTLV-1 p13(II) was also found to specifically interact with FPPS (in yeast as well as in GST pull-down assays) and to colocalize with G4 in mitochondria, suggesting a functional analogy between these oncoviral accessory proteins. Identification of FPPS as a molecular partner for p13(II) and G4 accessory proteins opens new prospects for treatment of retrovirus-induced leukemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11773414      PMCID: PMC135811          DOI: 10.1128/jvi.76.3.1400-1414.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

Review 1.  Novel anti-cancer agents in development: exciting prospects and new challenges.

Authors:  L Seymour
Journal:  Cancer Treat Rev       Date:  1999-10       Impact factor: 12.111

Review 2.  Mitochondria as the central control point of apoptosis.

Authors:  S Desagher; J C Martinou
Journal:  Trends Cell Biol       Date:  2000-09       Impact factor: 20.808

3.  The HTLV-I orfI protein is recognized by serum antibodies from naturally infected humans and experimentally infected rabbits.

Authors:  G A Dekaban; A A Peters; J C Mulloy; J M Johnson; R Trovato; E Rivadeneira; G Franchini
Journal:  Virology       Date:  2000-08-15       Impact factor: 3.616

4.  Dexamethasone-induced decrease in HMG-CoA reductase and protein-farnesyl transferase activities does not impair ras processing in AR 4-2J cells.

Authors:  M Lambert; N D Bui
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

5.  Functional role of pX open reading frame II of human T-lymphotropic virus type 1 in maintenance of viral loads in vivo.

Authors:  J T Bartoe; B Albrecht; N D Collins; M D Robek; L Ratner; P L Green; M D Lairmore
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma.

Authors:  P Matar; V R Rozados; E A Roggero; O G Scharovsky
Journal:  Cancer Biother Radiopharm       Date:  1998-10       Impact factor: 3.099

Review 7.  Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.

Authors:  E K Rowinsky; J J Windle; D D Von Hoff
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

8.  Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway.

Authors:  R K Keller; S J Fliesler
Journal:  Biochem Biophys Res Commun       Date:  1999-12-20       Impact factor: 3.575

9.  Proliferation response to interleukin-2 and Jak/Stat activation of T cells immortalized by human T-cell lymphotropic virus type 1 is independent of open reading frame I expression.

Authors:  N D Collins; C D'Souza; B Albrecht; M D Robek; L Ratner; W Ding; P L Green; M D Lairmore
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

10.  Evidence for the chronic in vivo production of human T cell leukemia virus type I Rof and Tof proteins from cytotoxic T lymphocytes directed against viral peptides.

Authors:  C Pique; A Ureta-Vidal; A Gessain; B Chancerel; O Gout; R Tamouza; F Agis; M C Dokhélar
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

View more
  30 in total

Review 1.  HTLV-1 p13, a small protein with a busy agenda.

Authors:  Micol Silic-Benussi; Roberta Biasiotto; Vibeke Andresen; Genoveffa Franchini; Donna M D'Agostino; Vincenzo Ciminale
Journal:  Mol Aspects Med       Date:  2010-03-21

Review 2.  The human T-cell leukemia virus type 1 p13II protein: effects on mitochondrial function and cell growth.

Authors:  D M D'Agostino; M Silic-Benussi; H Hiraragi; M D Lairmore; V Ciminale
Journal:  Cell Death Differ       Date:  2005-08       Impact factor: 15.828

3.  Human T-lymphotropic virus type 1 mitochondrion-localizing protein p13II sensitizes Jurkat T cells to Ras-mediated apoptosis.

Authors:  Hajime Hiraragi; Bindhu Michael; Amrithraj Nair; Micol Silic-Benussi; Vincenzo Ciminale; Michael Lairmore
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 4.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 5.  Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis.

Authors:  Björn Albrecht; Michael D Lairmore
Journal:  Microbiol Mol Biol Rev       Date:  2002-09       Impact factor: 11.056

6.  Suppression of tumor growth and cell proliferation by p13II, a mitochondrial protein of human T cell leukemia virus type 1.

Authors:  Micol Silic-Benussi; Ilaria Cavallari; Tatiana Zorzan; Elisabetta Rossi; Hajime Hiraragi; Antonio Rosato; Kyoji Horie; Daniela Saggioro; Michael D Lairmore; Luc Willems; Luigi Chieco-Bianchi; Donna M D'Agostino; Vincenzo Ciminale
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-20       Impact factor: 11.205

Review 7.  Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression.

Authors:  Michael Bindhu; Amrithraj Nair; Michael D Lairmore
Journal:  Front Biosci       Date:  2004-09-01

8.  Subcellular localization of the bovine leukemia virus R3 and G4 accessory proteins.

Authors:  Laurent Lefèbvre; Vincenzo Ciminale; Alain Vanderplasschen; Donna D'Agostino; Arsène Burny; Luc Willems; Richard Kettmann
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

Review 9.  HTLV-1 and apoptosis: role in cellular transformation and recent advances in therapeutic approaches.

Authors:  John M Taylor; Christophe Nicot
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

Review 10.  Mechanisms of HTLV-1 persistence and transformation.

Authors:  M Boxus; L Willems
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.